This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BHMT / Betaine--homocysteine S-methyltransferase 1 · IHC design guide
Design Immunohistochemistry for BHMT
Use liver hepatocytes and kidney proximal tubules as positive references for BHMT staining in paraffin sections (HPA tissue IHC). Start the IHC-validated catalog antibody A06712-2 at 2–5 μg/mL (datasheet A06712-2) and assess cytoplasmic staining (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
BHMT Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasm in hepatocytes and proximal tubules (HPA tissue IHC) | |
| Staining pattern | Cytoplasmic staining in hepatocytes and proximal tubules (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A06712-2) | |
| Positive control | Kidney+1 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across tissue sections. (standard IHC practice; not target-specific) | |
| Caveat | Oxidative stress may shift BHMT toward the nucleus (UniProt) | |
| Regulation | Liver and kidney enriched expression (HPA tissue IHC) | |
| Isoform / epitope | No annotated isoforms, signal peptide or propeptide (UniProt) |
Section 1
Recommended BHMT IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by four published BHMT IHC protocols (PMC11920202; PMC3871600; PMC9208444; PMC8112889).
| Sample | Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A06712-2) |
| Fixation | Image fixative and duration unreported (datasheet A06712-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A06712-2); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A06712-2) |
| Primary antibody | Rabbit anti-BHMT, 2-5 μg/ml (datasheet A06712-2) |
| Primary incubation | Overnight at 4 °C (datasheet A06712-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A06712-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | BHMT-positive staining in proximal tubules (cell body) of kidney (HPA tissue IHC: High). HPA tissue profile: Selective cytoplasmic expression in hepatocytes and kidney tubules. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval for the catalog antibody (datasheet: A06712-2). Published citrate protocols used different antibodies (PMC9208444; PMC8112889).
Section 2
What Is the Expected BHMT Staining Pattern?
BHMT should appear predominantly in the cytoplasm of hepatocytes and kidney proximal tubule cells, with high staining in both (HPA: tissue IHC). HPA rates the tissue pattern Enhanced, citing consistency between staining and RNA expression (HPA: tissue IHC). BHMT has no transmembrane segment; UniProt reports a small nuclear fraction and nuclear translocation under oxidative stress (UniProt Q93088: topology and subcellular location).
| Strong cytoplasmic staining in hepatocytes and proximal tubule cell bodies. | This matches the reported positive pattern. Judge hepatocytes and proximal tubules as cells, rather than treating all liver or kidney structures as equally positive (HPA: tissue IHC, High in hepatocytes and proximal tubules). |
| Nuclear staining dominates, or staining outlines cell membranes. | A predominantly nuclear or membrane pattern conflicts with the expected cytoplasmic IHC pattern (HPA: tissue IHC; UniProt Q93088: no transmembrane segment). A small nuclear fraction is reported, especially with oxidative stress, so nuclear signal alone is not proof of artefact (UniProt Q93088: subcellular location). |
| Strong staining appears in adipocytes or other HPA negative cell populations. | Consider antibody cross-reactivity or endogenous detection activity and check controls (standard IHC practice). HPA reports BHMT as not detected in adipocytes from adipose tissue and in its other listed negative cell populations; those observations do not define every cell in an organ (HPA: tissue IHC). |
| Brown signal is diffuse across cells, stroma, or the section edge. | Diffuse deposition that obscures the expected cell boundaries is background until controls establish otherwise (standard chromogenic IHC practice). It cannot be assigned to BHMT from appearance alone; compare it with the selective hepatocyte and proximal tubule pattern (HPA: tissue IHC). |
| Hepatocytes and proximal tubules show no detectable staining. | A blank known-positive sample raises a technical question before a biological conclusion: review tissue preservation, retrieval, primary-antibody conditions, and detection controls (standard IHC practice). HPA reports high staining in these cell types, but does not establish BHMT-specific fixation or retrieval sensitivity (HPA: tissue IHC). |
💡Expected BHMT appearanceCall a section positive when high cytoplasmic signal identifies hepatocytes or proximal tubule cell bodies (HPA: tissue IHC); dominant membrane staining or broad staining of HPA negative cell populations warrants investigation (UniProt Q93088: topology; HPA: tissue IHC).
| Cell and tissue selection | Liver hepatocytes and kidney proximal tubules are evidence-backed positive comparators; adipocytes in adipose tissue are one reported negative comparator (HPA: tissue IHC). Score the named cell population, since the supplied HPA result does not assign a single staining level to every cell in each tissue. |
| Subcellular location | Expect cytoplasmic IHC signal and allow for a small nuclear fraction; oxidative stress can shift BHMT toward the nucleus (HPA: tissue IHC; UniProt Q93088: subcellular location). A nuclear shift needs biological context and controls before interpretation. |
| Membrane and processing status | BHMT has no transmembrane segment, signal peptide, or propeptide, and its annotated chain spans residues 1–406 (UniProt Q93088: topology and processing). These annotations support a nonmembranous expectation; they do not specify an antibody epitope or predict retrieval performance. |
| Strength of the IHC evidence | HPA rates tissue staining Enhanced and lists two rabbit polyclonal antibodies with Enhanced IHC status, HPA038285 and HPA058310 (HPA: tissue IHC and antibodies). This supports the reported pattern; it does not validate an unspecified catalog antibody, dilution, or staining protocol. |
| Antigen retrieval and detection | Retrieval, blocking, and detection can affect chromogenic IHC readout (standard IHC practice). The supplied UniProt and HPA records give no BHMT-specific retrieval condition or fixation-effect result, so choose and assess these conditions using the actual antibody protocol and controls. |
| IF/ICC Q&A: what location should appear? | Predominantly cytosolic fluorescence is expected; HPA marks Cytosol as the approved ICC-IF location (HPA: subcellular ICC-IF). UniProt also notes a small nuclear fraction and stress-related nuclear translocation (UniProt Q93088: subcellular location). This location answer is not an IF/ICC protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in a liver or kidney positive comparator. | The stain may have failed at the primary-antibody, retrieval, or detection step; absence alone does not identify which step failed (standard IHC practice). | Inspect section quality and control reactions, then check the actual antibody's IHC-P instructions and detection reagents. Reassess hepatocytes and proximal tubules specifically (HPA: tissue IHC, High). |
| Signal is mainly nuclear in a nominally unstressed sample. | The pattern differs from predominantly cytoplasmic BHMT, although a small nuclear fraction and oxidative-stress translocation are reported (UniProt Q93088: subcellular location). | Check matched controls and whether the sample has an oxidative-stress context. Compare nuclear and cytoplasmic signal within the same cell population before calling it nonspecific (standard IHC interpretation). |
| Signal traces membranes or tubule lumens more strongly than cell bodies. | This diverges from selective cytoplasmic staining of proximal tubule cell bodies and from the lack of a transmembrane segment (HPA: tissue IHC; UniProt Q93088: topology). | Review morphology, counterstain, and detection controls; repeat with an appropriately validated primary antibody if the compartment pattern persists (standard IHC practice). |
| Adipocytes or another listed HPA negative population stain strongly. | Cross-reactivity or endogenous detection activity is possible (standard IHC practice); HPA reports BHMT as not detected in those specified cell populations (HPA: tissue IHC). | Run a no-primary control and assess endogenous detection activity appropriate to the detection chemistry. Check whether signal remains selective for hepatocytes and proximal tubules (standard IHC practice; HPA: tissue IHC). |
| Diffuse brown haze obscures the positive cell pattern. | Background from blocking, washing, or detection may prevent interpretation (standard chromogenic IHC practice). Haze cannot establish BHMT expression in an otherwise negative population. | Compare with the no-primary control; review blocking, wash steps, and detection development according to the staining system. Score only a clear cellular pattern (standard IHC practice). |
| A different antibody gives a conflicting tissue pattern. | HPA's Enhanced rating describes its reported tissue staining and listed antibodies; it does not establish performance of every antibody (HPA: tissue IHC and antibodies). | Check that the alternative antibody is validated for IHC-P, compare matched positive and negative cell populations, and document any unresolved discrepancy before assigning BHMT staining (HPA: tissue IHC; standard IHC practice). |
Experiment evidence
IHC & IF images showing BHMT staining
A06712-2 · IHCIHC analysis of BHMT using anti-BHMT antibody (A06712-2). BHMT was detected in a paraffin-embedded section of human bladder epithelial carci
A06712-2 · IHCIHC analysis of BHMT using anti-BHMT antibody (A06712-2). BHMT was detected in a paraffin-embedded section of human Classic Hodgkin's lympho
A06712-2 · IFIF analysis of BHMT using anti-BHMT antibody (A06712-2). BHMT was detected in an immunocytochemical section of U20S cells. Enzyme antigen re
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/cerebral+cortex#imid_9474324
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/colon#imid_9461162
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/liver#imid_9461147
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000145692-BHMT/tissue/kidney#imid_9461148
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA038285; green = BHMT, blue = nucleus, red = microtubules.
HPA · ICC-IF Hep-G2Human Protein Atlas immunofluorescence, Hep-G2, antibody HPA038285; green = BHMT, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for BHMT IHC & IF
🧪Run kidney first: proximal tubule cell bodies should stain strongly (HPA: High in proximal tubules). Use adipose tissue as the negative tissue (HPA: Not detected in adipocytes); on the kidney slide, compare staining with other renal compartments as an internal background reference, without treating them as confirmed BHMT-negative cells (HPA: High in proximal tubules).
Positive control tissue: Kidney (Proximal tubules (cell body), HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show BHMT in Hep-G2, U-251MG, U2OS, with annotated localisation: Cytosol (approved) (HPA subcellular).
Technical controls: Include no-primary (secondary-only), concentration-matched rabbit IgG isotype, and BHMT knockout tissue or peptide-blocked primary as specificity controls (A06712-2 IHC caption: rabbit primary; standard IHC practice). Block endogenous peroxidase and, if using the caption’s biotinylated secondary and avidin–biotin detection, check endogenous biotin in kidney (A06712-2 IHC caption: biotinylated secondary and SABC; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected A06712-2 paraffin-section caption does not state a fixative (A06712-2 IHC caption). That caption demonstrates heat-mediated EDTA retrieval at pH 8.0, but does not establish whether BHMT staining depends on that retrieval condition (A06712-2 IHC caption). Frozen sections and IF cannot be judged easier from the supplied evidence; kidney staining with avidin–biotin detection may be confounded by endogenous biotin (HPA: High in proximal tubules; A06712-2 IHC caption: SABC; standard IHC practice).
HPA tissue IHC evidence for BHMT
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — High consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Kidney | Proximal tubules (cell body) | High | Protein (IHC) | HPA → |
| Liver | Hepatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced BHMT IHC Tips
These questions focus on chromogenic BHMT IHC in paraffin sections, with one question addressing IF as a secondary application.
Which retrieval condition should I start with for BHMT IHC in paraffin sections?
Start with heat mediated retrieval in EDTA at pH 8.0 (datasheet A06712-2). The selected paraffin section was then stained with 2 μg/ml antibody overnight at 4°C, so use that documented combination as your starting point (datasheet A06712-2). Include a liver or kidney section to check whether retrieval exposes the expected cytoplasmic signal in hepatocytes or kidney tubules (HPA: tissue IHC profile). If staining is weak, adjust heating duration on matched sections while holding antibody concentration and detection conditions constant (general IHC practice). Compare morphology and signal together, because excessive heating can damage sections and complicate interpretation (general IHC practice).
How should I troubleshoot variable BHMT staining between differently fixed sections?
Target specific fixation sensitivity is unknown: the selected paraffin tissue caption does not state a fixative (datasheet A06712-2). Record each specimen’s fixative, fixation interval and processing history before comparing staining, because these variables can alter antigen accessibility in IHC (general IHC practice). Run differently processed sections together with the same pH 8.0 EDTA retrieval and detection settings to identify a processing associated change (datasheet A06712-2; general IHC practice). Use liver hepatocytes or kidney tubules as positive reference compartments when available (HPA: tissue IHC profile). Do not attribute a difference to a BHMT specific fixation effect without a controlled comparison (general IHC practice).
Where should BHMT staining appear, and how should nuclear signal be assessed?
Expect mainly cytoplasmic staining in hepatocytes and kidney tubules (HPA: tissue IHC profile; UniProt Q93088: predominant cytoplasmic localisation). Assess nuclear staining separately from cytoplasmic intensity rather than pooling both compartments into one score (general IHC practice). A small nuclear fraction is reported, with nuclear translocation upon oxidative stress (UniProt Q93088: subcellular localisation). Therefore, document specimen context and compare nuclear signal against the cytoplasmic pattern in the same cells before proposing stress associated redistribution (UniProt Q93088: subcellular localisation; general IHC practice). Diffuse nuclear staining across unrelated cells warrants review of controls, counterstain and detection background (general IHC practice).
Could an isoform or epitope issue explain patchy BHMT staining?
The supplied record lists 0 BHMT isoforms and one chain spanning residues 1–406 (UniProt Q93088: isoforms and processing). It does not map the catalog antibody’s epitope, so a specific residue level retrieval or modification effect cannot be assigned (datasheet A06712-2: epitope not stated). BHMT has an Hcy binding region at residues 11–314 and recorded modified residues, including phosphoserine 330 (UniProt Q93088: domains and modified residues). Compare patchy staining with morphology, section processing and a positive reference before invoking epitope masking (general IHC practice; HPA: high hepatocyte and kidney tubule staining). If necessary, test an independently characterized antibody with a known epitope (general IHC practice).
How can I adapt BHMT localisation checks to multiplex IF?
Pair BHMT with a marker for the expected hepatocyte or kidney tubule population, and score colocalisation at the cell level (HPA: tissue IHC profile; general IF practice). BHMT is principally cytosolic and has no transmembrane segment, so use permeabilisation compatible with access to a cytosolic epitope (HPA: subcellular; UniProt Q93088: topology; general IF practice). Choose fluorophores and filter settings after examining unstained tissue autofluorescence, then include single stain controls when multiplexing (general IF practice). Assess any nuclear redistribution separately, since a small nuclear fraction and stress associated translocation are reported (UniProt Q93088: subcellular localisation). Optimize IF fixation independently; the selected IHC caption leaves fixation unspecified (datasheet A06712-2).
What should I check when DAB appears outside expected BHMT positive cells?
Use liver hepatocytes or kidney tubules as positive references and compare background in cells expected to lack detectable BHMT (HPA: tissue IHC profile). The selected procedure used 10% goat serum, biotinylated secondary antibody, a streptavidin biotin complex and DAB (datasheet A06712-2). Include a no primary control and check endogenous peroxidase blocking when diffuse DAB persists (general chromogenic IHC practice). With a biotin based detection system, assess endogenous biotin as a possible contributor to background (datasheet A06712-2: detection system; general IHC practice). Recheck washes and antibody concentration before interpreting staining in unexpected compartments as BHMT (general IHC practice).
How should I quantify BHMT IHC across specimens with different cell composition? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring: hepatocyte and kidney tubule cytoplasm are the expected positive sites (HPA: tissue IHC profile). Report the percentage of positive target cells and an intensity based H-score from 0–300, with nuclear staining recorded separately if present (general IHC practice; UniProt Q93088: subcellular localisation). Normalize counts to the number of evaluable target cells, or report stained cell density per mm² of annotated tissue area (general IHC practice). Apply the same threshold, imaging settings and exclusion criteria across sections (general IHC practice). Exclude damaged edges and necrotic regions from the denominator and document those exclusions (general IHC practice).
How do I distinguish convincing BHMT signal from chromogenic artefact?
A convincing pattern is predominantly cytoplasmic staining in hepatocytes or kidney tubules, with high signal reported in both populations (HPA: tissue IHC profile; HPA: high hepatocytes and proximal tubules). Treat strong staining in unrelated cells or uniformly nuclear staining as a finding requiring control review, while allowing for the reported small nuclear fraction (HPA: tissue IHC profile; UniProt Q93088: subcellular localisation). Check whether signal concentrates at section edges or necrotic areas, where staining can be misleading (general IHC practice). Compare a no primary control to assess detection background, including endogenous peroxidase contribution to DAB (general chromogenic IHC practice). Interpret unexpected positives alongside morphology and matched positive reference sections (general IHC practice).
Boster reagents
Best BHMT / Betaine--homocysteine S-methyltransferase 1 IHC Antibodies
A06712-2 has IHC images from human paraffin sections and an IF/ICC image from U20S cells (catalog image captions). Its listed reactivity covers human, mouse, and rat (catalog).
Real IHC data
Anti-BHMT Antibody ®
Cat # A06712-2
A06712-2 will render with a human bladder epithelial carcinoma paraffin-section IHC figure; other supplied captions show human tissue IHC and U20S cell IF/ICC (catalog image captions). M06712-2 is listed for human IHC, but no IHC or IF image is supplied for it (catalog).
Which to pick: For tissue IHC, choose A06712-2: its own figure documents staining in a human paraffin section after EDTA retrieval, although the fixative is unreported (A06712-2 IHC caption). For IF/ICC, choose A06712-2 because its U20S cell IF image is supplied; M06712-2 is a rabbit monoclonal listed for human IHC, with no supplied IF image (A06712-2 IF caption; catalog). For mouse or rat samples, A06712-2 has the relevant listed reactivity, but its supplied tissue IHC images are from human samples (catalog; A06712-2 IHC captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q93088 (BHMT1_HUMAN, Betaine--homocysteine S-methyltransferase 1).
- Human Protein Atlas. BHMT tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. BHMT subcellular location (ICC-IF): Localized to the cytosol..
- Human Protein Atlas. BHMT antibody validation summary (2 antibodies).
- Identification of methionine metabolism related prognostic model and tumor suppressive functions of BHMT in hepatocellular carcinoma. Scientific reports 2025 — PMC11920202.
- Homocysteine homeostasis and betaine-homocysteine S-methyltransferase expression in the brain of hibernating bats. PloS one 2013 — PMC3871600.
- Increased homocysteine regulated by androgen activates autophagy by suppressing the mammalian target of rapamycin pathway in the granulosa cells of polycystic ovary syndrome mice. Bioengineered 2022 — PMC9208444.
- The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation. PloS one 2021 — PMC8112889.
- PubMed PMID:8798461 — UniProt-cited evidence.
- PubMed PMID:10075673 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for BHMT (Betaine--homocysteine S-methyltransferase 1). Expected localisation Cytoplasm in hepatocytes and proximal tubules (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A06712-2). Validated IHC antibody: A06712-2 at 2-5 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Kidney (Proximal tubules (cell body)); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human bladder epithelial carcinoma tissue; fixative not specified (datasheet A06712-2); 2. Fixation: Image fixative and duration unreported (datasheet A06712-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A06712-2); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A06712-2); 8. Primary antibody: Rabbit anti-BHMT, 2-5 μg/ml (datasheet A06712-2); 9. Primary incubation: Overnight at 4 °C (datasheet A06712-2). Watch for: Fixation: Keep fixation consistent across tissue sections. (standard IHC practice; not target-specific); Caveat: Oxidative stress may shift BHMT toward the nucleus (UniProt); Isoform / epitope: No annotated isoforms, signal peptide or propeptide (UniProt); Regulation: Liver and kidney enriched expression (HPA tissue IHC). Evidence: UniProt Q93088, HPA tissue IHC · Enhanced, HPA ICC-IF · cytosol., Datasheet A06712-2, PMC11920202, PMC3871600. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/BHMT/immunohistochemistry-ihc-guide.